Vaccines 2020: World Market Analysis, Players, Trends

"Vaccine Market Tops 37 Billion", Says Kalorama Information Report.

In 2020, the global market for preventive vaccines is valued at $37.4 billion, up overall from $30.7 billion in 2015. The finding was made in Kalorama Information's report, ‘Vaccines 2020’. Strong continued growth in the global vaccines market is expected through 2025.

THE MOST CURRENT VACCINE MARKET INFORMATION

The vaccine market is a growth market for the experienced competitors participating in it.Seven billion dollars in new sales have occurred in the past five years alone, and vaccines have been developed and deployed for new diseases. COVID-19 has only intensified the focus on the the potential of vaccines, the market was already expanding prior to the pandemic, and many vaccines for new conditions are under developments. Kalorama has covered the vaccines market for two decades. During that time our analysts have detailed the growth of the market.

"Seven billion dollars in new sales have occurred in the past five years alone. Growth will be fueled by favorable demographics, continued new product introductions, indication expansions, usage and more."

This report examines the market for these vaccines used to prevent various types of disease, and provides market modeling by disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines for diseases that are not currently vaccine-preventable, such as addiction and malaria. The report also discusses trends and looks at what vaccine companies have done and are planning. It also covers the COVID-19 vaccine market landscape, development progress and estimated market opportunity as of October 2020.

A HIGH-GROWTH, CONSTANTLY DEVELOPING MARKET

                                                Vaccines Market, $BN, 2015, 2020 and 2025

Because of the large number of deadly diseases that have been virtually eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements during the 20th century. As a result of widespread public vaccination, vaccine-preventable diseases and their resulting deaths are now rare in the developed nations and declining worldwide. Immunizations have eradicated smallpox; eliminated poliomyelitis in the Americas; and controlled measles, rubella, tetanus, diphtheria.

FACTORS DRIVING GROWTH

• Cost-effectiveness: Vaccines reduce healthcare costs associated with vaccine-preventable diseases. It is estimated that every dollar invested in vaccination returns between $7 and $20 in averted healthcare costs;

• Aging population: As senior citizens are more susceptible to certain vaccine-preventable diseases such as influenza, more vaccine products are required to meet the needs of this growing global population;

• Mobility: As people become increasingly mobile, diseases historically confined to remote areas of the world are becoming global problems;

• Advancing technology: New technologies will fuel the development of vaccines that are safer, more effective and more cost effective to produce than existing vaccines;

• Usage of vaccines in more countries: WHO and other initiatives to expand immunization programs continue to increase the usage of vaccines in countries with previously poor vaccination records;

• Rising public awareness: Direct-to-consumer (DTC) advertising and other public awareness programs will continue to expand consumer awareness of the importance of vaccination;

• Government recommendations: Governments around the world continue to review and expand vaccination recommendations;

• Indication expansions: Manufacturers are increasingly expanding the populations for which their vaccines may be utilized;

• Healthcare Reform: Because all ACIP-recommended vaccines are covered under Healthcare Reform, millions of Americans who were previously uninsured now have coverage for vaccines;

• Healthcare decentralization: Expansion of retail health clinics and urgent care centers makes vaccination available to persons without strong health coverage;

Greater expansion is mitigated, however, by continued negative public perceptions of vaccine safety, shortages, funding challenges

KALORAMA INFORMATION'S REPORT PROVIDES
CRITICAL INSIGHTS FOR BUSINESS PLANNING

As part of its offering this report involves the following data points and others:

• Influenza Vaccine Global Market, 2020-2025

• US, European, and ROW Vaccine Markets by Type (Hepatitis, Combinations, Meningitis, Pneumococcal, Rotavirus, Influenza, HPV, Shingles, Others)

• Major Manufacturers' Shares of the Global Vaccine Market, 2020

• Global Market for Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, HPV, Others) 2020-2025

• Global Market for Adult Preventive Vaccines by Type (Hepatitis, HPV, Pneumococcal, Tetanus and combinations, Shingles, Travel & Other) 2020-2025

• Selected Pediatric Vaccines in Development, 2020

• Selected Adult Vaccines in Development, 2020

• COVID-19 Vaccine Developments

• COVID-19 Vaccine Potential Market Estimate, High Case and Low Case

Development of new vaccines is ongoing. Generally speaking, vaccine clinical development in the world's major markets follows a similar pathway as drugs and other biologics. A sponsor who wishes to begin clinical trials with a vaccine must first obtain permission to conduct clinical studies. In the U.S., this requires the submission of an Investigational New Drug (IND) application to the FDA.

"mitigating against growth will be continuing concerns about vaccine safety and refusal to immunize."

The IND describes the vaccine, its method of manufacture, and quality control tests for release. Also included is information about the vaccine's safety and ability to elicit a protective immune response (immunogenicity) in animal testing as well as the proposed clinical protocol for studies in humans. Kalorama's report tracks development of vaccines, including those for COVID-19.

The report as well reviews the history and lines of business, strategic alliances, vaccine products, and financial information of market leaders such as GlaxoSmithKline, Merck, Pfizer, and Sanofi Pasteur.

COMPANY COVERAGE

Companies Covered in the Report Include:

• ADVAXIS
• BAVARIAN NORDIC, A/S
• BHARAT BIOTECH INTERNATIONAL
• CSL LIMITED/SEQIRUS
• EMERGENT BIOSOLUTIONS
• GLAXOSMITHKLINE
• HAWAII BIOTECH
• IMMUNE RESPONSE BIOPHARMA
• INOVIO PHARMACEUTICALS
• JOHNSON & JOHNSON/CRUCELL/JANSSEN
• MEDICAGO
• MERCK & CO
• MITSUBISHI TANABE PHARMA CORPORATION
• MODERNA
• NOVAVAX
• PFIZER
• SANOFI PASTEUR
• SERUM INSTITUTE
• SOLIGENIX
• TAKEDA PHARMACEUTICAL CO
• VALNEVA SE

MARKET SIZING - MARKET FORECASTS - COMPANY SEGMENTATION - COMPANY SHARE - COMPANY PROFILES - Reserve Your Copy of This Report Today.

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

• THE GLOBAL VACCINES INDUSTRY
• SCOPE AND METHODOLOGY

• MARKET ESTIMATES AND FORECASTS
  • Figure 1-1: Global Vaccine Market, 2020 - 2025, $M

CHAPTER 2: INTRODUCTION TO VACCINES

• INTRODUCTION
  • Table 2-1: Global Morbidity of Vaccine Preventable Diseases in 1990 vs. 2019
  • Figure 2-1: CDC Infographic: Global Impact of Vaccines in Reducing Vaccine-Preventable Disease Morbidity and Mortality

• A BRIEF HISTORY: THE DEVELOPMENT OF VACCINES
• THE HUMAN IMMUNE SYSTEM
• VACCINE MECHANISM OF ACTION

• TYPES OF VACCINES
  • Attenuated (Weakened) Live Viruses
  • Figure 2-2: Attenuated Virus Production
  • Killed (Inactivated) Viruses
  • Toxoid Vaccines
  • Genetically Engineered/Modified Vaccines

• VACCINE APPROVAL PROCESS
  • Table 2-2: VAERS Table of Reportable Events Following Vaccination

• WORLD HEALTH ORGANIZATION PREQUALIFIED VACCINES
  • Table 2-3: WHO Prequalified BCG Vaccines
  • Table 2-4: WHO Prequalified Cholera Vaccines
  • Table 2-5: WHO Prequalified Diphtheria-Tetanus Vaccines
  • Table 2-6: WHO Prequalified Diphtheria-Tetanus-Pertussis Vaccines
  • Table 2-7: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hemophilus influenzae type b Vaccines
  • Table 2-8: WHO Prequalified Diphtheria-Tetanus-Pertussis and Hepatitis B Vaccines
  • Table 2-9: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hepatitis B-Hemophilus influenzae type b Vaccines
  • Table 2-10: WHO Prequalified Hemophilus influenzae type b Vaccines
  • Table 2-11: WHO Prequalified Hepatitis A Vaccines
  • Table 2-12: WHO Prequalified Hepatitis B Vaccines
  • Table 2-13: WHO Prequalified Human Papillomavirus Vaccines
  • Table 2-14: WHO Prequalified Influenza Vaccines
  • Table 2-15: WHO Prequalified Japanese Encephalitis Vaccines
  • Table 2-16: WHO Prequalified Measles Vaccines
  • Table 2-17: WHO Prequalified Measles and Rubella Vaccines
  • Table 2-18: WHO Prequalified Measles, Mumps and Rubella Vaccines
  • Table 2-19: WHO Prequalified Meningococcal A Vaccines
  • Table 2-20: WHO Prequalified Pneumococcal Vaccines
  • Table 2-21: WHO Prequalified Polio Vaccines
  • Table 2-22: WHO Prequalified Rabies Vaccines
  • Table 2-23: WHO Prequalified Rotavirus Vaccines
  • Table 2-24: WHO Prequalified Rubella Vaccines
  • Table 2-25: WHO Prequalified Tetanus Toxoid Vaccines
  • Table 2-26: WHO Prequalified Typhoid Vaccines
  • Table 2-27: WHO Prequalified Varicella Vaccine
  • Table 2-28: WHO Prequalified Yellow Fever Vaccines

• PANDEMICS
  • HIN1 Pandemic of 2009/2010
  • Coronavirus Pandemic
    • Figure 2-3: COVID-19 Per Capita Doses Ordered by Country
    • Figure 2-4: COVID-19 Vaccine Candidates: Government Presales
  • Ebola Epidemic 2014-2016
  • Manufacturing Incentives
  • Synthetic Vaccines

• ARTIFICIAL INTELLIGENCE DEVELOPMENT

CHAPTER 3: PEDIATRIC PREVENTATIVE VACCINES

• INTRODUCTION
  • Table 3-1: Global Child Immunization Rates for Vaccines Recommended by the WHO, 2019

• CHILDHOOD IMMUNIZATION IN THE UNITED STATES
  • Childhood Immunization Rates
  • Challenges to the Vaccine Delivery System
  • Recommended Childhood Immunization Schedule
    • Figure 3-1: CDC Recommended Immunization Schedule: Birth to 15 Months
    • Figure 3-2: CDC Recommended Immunization Schedule: 18 Months to 18 Years
  • State Immunization Recommendations
    • Figure 3-3: Polar Graph on State School Vaccination Exemptions Law, United States
  • United Nations Initiatives

• PEDIATRIC VACCINE MARKETS
  • Table 3-2: Global Market for Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Others) 2020-2025, in $ Millions
  • Figure 3-4: Global Market for Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Others) 2020-2025 (%)
  • Figure 3-5: Market Share of Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Others) 2020 (%)

• PEDIATRIC VACCINES IN DEVELOPMENT
  • Table 3-3: Selected Pediatric Vaccines in Development, 2020

• COMPETITIVE SUMMARY
  • Table 3-4: Major Manufacturers' Shares of the Global Pediatric Preventative Vaccine Market, 2020 (%, $ Millions)
  • Figure 3-6: 2020 Global Pediatric Preventative Vaccines Market Share, by Leading Competitors (%)

CHAPTER 4: ADULT PREVENTATIVE VACCINES

• INTRODUCTION

• RECOMMENDED ADULT IMMUNIZATIONS
  • Figure 4-1: CDC Recommended Immunization Schedule: Adults, 19 years and over

• GLOBAL INFLUENZA SURVEILLANCE PROGRAM
  • U.S. Surveillance
    • Table: 4-1: U.S. Influenza Vaccine Effectiveness, 2004 - 2020 (%)

• WHO International Health Regulations
  • Influenza
    • Figure 4-2: U.S. Flu Season Severity from 2008 to 2018
    • Table 4-2: WHO Pandemic Classification Schedule

• ADULT PREVENTIVE VACCINE MARKETS
  • Table 4-3: Global Market for Adult Preventive Vaccines by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Travel & Other) 2020-2025, in $ Millions
  • Figure 4-3: Global Market for Adult Preventive Vaccines by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Travel & Other) 2020-2025 (%)
  • Figure 4-4: Market Share of Adult Preventive Vaccines by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Travel & Other) 2020 (%)

• Influenza Vaccine Market: Generating 28% of Total Adult Vaccine Sales
  • Figure 4-5: U.S. Seasonal Influenza Vaccination by Age Group and Season, 2010-2020
  • Figure 4-6: U.S. Seasonal Influenza Vaccination Coverage and HP 2020 Target - Total Population - Seasons 2010-2020

• COVID-19 Market Size Estimates and Forecast

• ADULT VACCINES IN DEVELOPMENT
  • Table 4-4: Selected Adult Preventive Vaccines in Development, 2020

• COVID-19 Vaccine Development
  • Figure 4-7: Regional Distribution of COVID-19 Vaccine Development
  • Figure 4-8: COVID-19 Vaccine Development, Distribution by Vaccine Platform
  • Table 4-5: Select Vaccines in Development for COVID-19 - Phase I through Phase III

• COMPETITIVE SUMMARY
  • Table 4-6: Major Manufacturers' Shares of the Global Adult Preventative Vaccine Market, 2020 (%, $ Millions)
  • Figure 4-9: 2020 Global Adult Preventative Vaccines Market Share, by Leading Competitors (%)

CHAPTER 5: TOTAL VACCINES MARKET

• TRENDS DRIVING THE VACCINES MARKET
  • Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals, 2015-2025

• MARKET SIZE AND FORECAST
  • Table 5-1: Total Global Market for Preventive Vaccines by Type, 2020-2025, in $ Millions
  • Figure 5-2: Total World Market for Vaccines by Type, 2015-2024 (Pediatric, Adult) ($ Millions) 1

• Adult Vaccines
  • Figure 5-3: Global Preventive Vaccine Market by Broad Segment (Pediatric, Adult), Trend 2015 - 2025 $millions

• Vaccine Sales by Region
  • Table 5-2: Total U.S. Market for Preventive Vaccines by Type, 2020-2025, in $ Millions
  • Table 5-3: Total Europe Market for Preventive Vaccines by Type, 2020-2025, in $ Millions
  • Table 5-4: Total ROW Market for Preventive Vaccines by Type, 2020-2025, in $ Millions

• VACCINE MARKET COMPETITORS
  • Table 5-5: Major Manufacturers' Shares of the Global Vaccine Market, 2020 (%, $ Millions)
  • Figure 5-4: 2020 Global Vaccines Market Share, by Leading Competitors (%)

• COVID-19 VACCINE MARKET
  • Table 5-6: Global COVID-19 Vaccine Market Forecast, 2021 ($ millions)
  • Table 5-7: Global COVID-19 Vaccination Rate Forecast, (United States, Europe) 2021 %
  • Table 5-8: Global COVID-19 Vaccine Stockpiling and Government Contracts, Q4 2020 - 2025, Total Value ($M)
  • Figure 5-5: Global COVID-19 Vaccine Stockpiling and Government Contracted Dose Order Distribution based on $ Value, Q4 2020 - 2025, % by Country

• GLOBAL HEALTHCARE MERGERS AND ACQUISITIONS
  • Figure 5-6: Total U.S. Healthcare M&A Deal Value, 2010-2019, in $ Billions

• RECENT VACCINE ACTIVITY BY KEY PLAYERS: 2020 DEVELOPMENTS
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer
  • Sanofi

CHAPTER 6: COMPANY PROFILES

• ADVAXIS, INC.
  • Table 6-1: Advaxis Corporate Summary
  • Company Summary
  • Products

• BAVARIAN NORDIC, A/S
  • Table 6-2: Bavarian Nordic A/S Corporate Summary
  • Company Summary
  • Products

• BHARAT BIOTECH INTERNATIONAL LTD.
  • Table 6-3: Bharat Biotech Corporate Summary
  • Company Summary
  • Products

• CSL LIMITED/SEQIRUS
  • Table 6-4: CSL/Seqirus Corporate Summary
  • Company Summary
  • Products

• EMERGENT BIOSOLUTIONS, INC.
  • Table 6-5: Emergent BioSolutions Corporate Summary
  • Company Summary
  • Products

• GLAXOSMITHKLINE, INC.
  • Table 6-6: GlaxoSmithKline Corporate Summary
  • Company Summary
  • Products
  • Table 6-7: GSK Marketed Vaccines 2020
  • Table 6-8: GSK Vaccines in Development 2020

• HAWAII BIOTECH, INC.
  • Table 6-9: Hawaii Biotech Corporate Summary
  • Company Summary
  • Products

• IMMUNE RESPONSE BIOPHARMA, INC.
  • Table 6-10: Immune Response Biopharma Corporate Summary
  • Company Summary
  • Products

• INOVIO PHARMACEUTICALS, INC.
  • Table 6-11: Inovio Corporate Summary
  • Company Summary
  • Products

• JOHNSON & JOHNSON/CRUCELL/JANSSEN
  • Table 6-12: Johnson & Johnson Corporate Summary
  • Company Summary
  • Products

• MEDICAGO, INC.
  • Table 6-13: Medicago Corporate Summary
  • Company Summary
  • Products

• MERCK & CO, INC.
  • Table 6-14: Merck Corporate Summary
  • Company Summary
  • Products

• MITSUBISHI TANABE PHARMA CORPORATION
  • Table 6-15: Mitsubishi Tanabe Corporate Summary
  • Company Summary
  • Products

• MODERNA, INC
  • Table 6-16: Moderna Corporate Summary
  • Company Summary
  • Products

• NOVAVAX, INC.
  • Table 6-17: NovaVax Corporate Summary
  • Company Summary
  • Products

• PFIZER, INC.
  • Table 6-18: Pfizer Corporate Summary
  • Company Summary
  • Products

• SANOFI PASTEUR
  • Table 6-19: Sanofi Pasteur Corporate Summary
  • Company Summary

• SERUM INSTITUTE, INC.
  • Table 6-20: Serum Institute of India Corporate Summary
  • Company Summary
  • Products

• SOLIGENIX, INC.
  • Table 6-21: Soligenix Corporate Summary
  • Company Summary
  • Products

• TAKEDA PHARMACEUTICAL CO, LTD.
  • Table 6-22: Takeda Pharmaceutical Corporate Summary
  • Company Summary
  • Products

• VALNEVA SE
  • Table 6-23: Valneva Corporate Summary
  • Company Summary
  • Products